| HOME >> BIOLOGY >> TECHNOLOGY |
legal court opinion on a patient's medical status.
The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient's condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient's condition and to prescribe the proper medication.
The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this.
The Company will continue to provide its shareholders and investors with timely updates.
For more information, do not hesitate to contact us by using the form on our corporate website at neuro-biotechcorp.com. Your request will be transferred to the appropriate person and we will get back to you as soon as possible.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or perf
'/>"/>
| SOURCE Neuro-Biotech Corp. Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
2. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
5. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
6. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
7. China-Biotics Provides Further Updates on Qingpu New Facility
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. BioMS updates corporate strategy and adds leading healthcare investment banker
11. BioMS Medical updates University of Alberta equity position
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |